Silencing human genetic diseases with oligonucleotide-based therapies
- 14 March 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Human Genetics
- Vol. 132 (5), 481-493
- https://doi.org/10.1007/s00439-013-1288-1
Abstract
RNA interference is an endogenous mechanism present in most eukaryotic cells that enables degradation of specific mRNAs. Pharmacological exploitation of this mechanism for therapeutic purposes attracted a whole amount of attention in its initial years, but was later hampered due to difficulties in delivery of the pharmacological agents to the appropriate organ or tissue. Advances in recent years have to a certain level started to address this specific issue. Genetic diseases are caused by aberrations in gene sequences or structure; these particular abnormalities are in theory easily addressable by RNAi therapeutics. Sequencing of the human genome has largely contributed to the identification of alterations responsible for genetic conditions, thus facilitating the design of compounds that can address these diseases. This review addresses the currently on-going programs with the aim of developing RNAi and other antisense compounds for the treatment of genetic conditions and the pros and cons that these products may encounter along the way. The authors have focused on those programs that have reached clinical trials or are very close to do so.Keywords
This publication has 88 references indexed in Scilit:
- RNA-Based Therapeutics: Current Progress and Future ProspectsCell Chemical Biology, 2012
- Familial Hypercholesterolemia: Present and Future ManagementCurrent Cardiology Reports, 2011
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyThe Lancet Neurology, 2009
- RNA and DiseaseCell, 2009
- Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenitaJournal of Dermatological Science, 2008
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic MiceAmerican Journal of Human Genetics, 2008
- Liquid movement across the surface epithelium of large airwaysRespiratory Physiology & Neurobiology, 2007
- Modification of globin gene expression by RNA targeting strategiesExperimental Hematology, 2007
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007
- Molecular biology of PCSK9: its role in LDL metabolismTrends in Biochemical Sciences, 2007